352705-03-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(2R)-2-[(tert-butoxycarbonyl)amino]propyl 4-methylbenzene-1-sulfonate is used as a protecting group for amines in the pharmaceutical industry. It allows chemists to selectively modify other parts of a molecule without affecting the amine group, which is crucial for the synthesis of complex drug molecules.
Used in Agrochemical Synthesis:
In the agrochemical industry, (2R)-2-[(tert-butoxycarbonyl)amino]propyl 4-methylbenzene-1-sulfonate is also utilized as a protecting group for amines. This helps in the synthesis of complex agrochemical molecules, ensuring that the amine group remains protected during the reaction process.
Used as a Building Block:
(2R)-2-[(tert-butoxycarbonyl)amino]propyl 4-methylbenzene-1-sulfonate is used as a building block in the synthesis of more complex molecules for both pharmaceutical and agrochemical applications. Its protective Boc group and solubility-enhancing 4-methylbenzene-1-sulfonate moiety make it a versatile component in molecular construction.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 79069-13-9 (R)-2-tertbutoxycarbonylamino-1-propanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 942999-00-0 methyl (R)-4-[2-(tert-butyloxycarbonylamino)propyloxy]-3,5-dimethylbenzoate 
• 170367-68-7 (2-cyano-1(R)-methylethyl)carbamic acid, 1,1-dimethylethyl ester 
• 1006584-09-3 C₃₀H₄₂ClN₃O₅ 
• 942999-01-1 (R)-4-[2-(tert-butyloxycarbonylamino)propyloxy]-3,5-dimethylbenzoic acid 

Relevant academic research and scientific papers

BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2

The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator

Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided

THERAPEUTIC COMPOUNDS

This invention relates to a novel class of substituted amino-ethoxy benzene derivatives of formula (I) which are inhibitors of serine proteases and to their use in treating aberrant serine protease activity in a mammal, contraception, anti-coagulant methods and methods for treating aberrant cell proliferation, tumours, cancer, angiogenesis, angiogenesis-based retinopathies, autoimmummune disease, inflammation, skin disease, arthritis, rheutmatoid arthritis, asthma, osteoarthritis and multiple sclerosis. (I), Wherein Rm, Rn, Rp, Rq, V, W, X, Y and R8 are as defined in the claims.

Cannabimimetic lipid amides as useful medications

Novel analogs of arachidonylethanolamide are presented which have higher affinities for the cannabinoid CB1 and/or CB2 receptor sites. Further, most of the analogs exhibit greater metabolic stability than arachidonylethanolamide. The improved receptor aff